Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 Black Phoenix Black Phoenix +335.82%
#4 aPriori aPriori +148.53%
#5 Bedrock Bedrock +75.14%
#6 Cysic Cysic +50.00%
#7 Prom Prom +47.31%
#8 Playnance Playnance +34.96%
#9 Bitway Bitway +29.10%
#10 COTI COTI +25.76%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Adynxx, Inc. Adynxx, Inc.

Adynxx, Inc.

ADYX
Rank in Stocks #42632
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating... Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$581.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Adynxx, Inc. (ADYX)

Category

Healthcare
P/E ratio for Adynxx, Inc. (ADYX)
P/E ratio as of 2026 TTM: 0
According to Adynxx, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Adynxx, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.